Crohn's disease
The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.
The company has slightly extended its timeline for launching a Lyme disease test to focus on marketing its COVID assay for immunocompromised individuals.
ProciseDx Enters Markets for Inflammation, Medication Monitoring With Five-Minute POC Instrument
Premium
The firm has developed an instrument that uses fingerstick blood or stool samples to enable quantitative results for the management of conditions caused by inflammation.
The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.